Clinical Trial Update: A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating furmonertinib plus platinum-based chemotherapy versus osimertinib in patients with EGFR-sensitizing mutation-positive non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: NSCLC Patients With Brain Metastasis | Phase 3 | Status: RECRUITING